# I. Introduction nflammation is the body response to any type of injury, in which various mediators are released in surrounding environment. Recent debated topic is inflammation associated onco -promotion in tumor microenvironment. Inflammatory mediators in oraltumor micro-environment consists of mediators of inflamemation are Neutrophils, lymphocytes, macrophages, Natural killer cells, Dendritic cells secreting cytokines. Which can induce Immuno-modulation by myeloid derived suppressor cells (MDSC) results in Oral tumor promotion, progression, and metastasis (1). editing, immuneprocessing and immuneevasion. Immunoevasion is one of the hallmark of tumor in order to progress. Immunoevasion mechanism involves the production of cytokines, which are immunosuppressive, T cell apoptosis or loss of HLA class1 and costimulatory molecules. In Immunoediting high immunogenicity tumorseliminate tumor by NK cells, macrophages,T cells. Reduced tumor cell variant immunogenicity favour tumor progression by immunosuppression or resistant to immune attack. Immuno processing stage genetic instability and heterogeneity of cancer cells favour promotion of tumor which, are poorly recognized by immune system or immunosuppression. Immunoescape stage altered by expression of MHC1 and 11 and costimulatory molecules, antigen processing dysregulation antigen processing, expression of low levels tumor antigen, other mechanisms of immunosuppression are T cell tolerance to tumor antigen and immunosuppressive cytokines IL-10,TGF-Beta or T regulatory cells (Treg). (48) Oral cancer is an eighth most common cancer in the worldwide. Every year nearly 300,400 new cases have been reporting worldwide and costs 145,400 lives a year. Squamous cell carcinoma involves 90% of head and neck region especially from mucosal epithelium linked to various adverse habits such as smoking form of tobacco, smokeless tobacco, alcohol drinking and also human papilloma virus. Advance oral cancer locally, management has been a challenging issue involving multidisciplinary approach of surgery, chemotherapy and radiotherapy. Despite recent improvement in management of oral cancer still the prognosis is grave with five year survival rate nearly 50%. Early stage of inflammation neutrophils are predominant leucocyte and first cell to migrate are regulated by macrophages and mast cells in tissue. As inflammation proceeds various types of leucocytes majority of them are lymphocytes gets activated and recruited to the inflammatory site by a signalling network involving chemokines, cytokines, growth factors for defense against infection. Shifting of antimicrobial tissue damage to tissue repair occurs mediated by PGE2, TGF-Beta and reactive oxygen and nitrogen intermediates having dual role in both aggravating and suppressing inflammation. Resolution of inflammation requires macrophages, dendritic cells and phagocytes by apoptosis and phagocytosis, which promote an anti-Immune cells has an important role in preventing or promoting cancer through immune surveivellance of tumor by mechanism of immune-inflammatory response. If inflammation is dysregulated, aggravating to chronic inflammatory cellular respose causing immunosuppression, tissue and DNA damage by cytokines, growth factors, reactive oxygen and nitrogen species released from macrophages and lymphocytes (1,2). # II. # Factors Affecting Inflammation Induced Immunosuppression in Tumor Microenvironment of Oral Cancer Oral tumor microenvironment consists of various heterogeneous inflammatory mediators such as neutrophils, natural killer cells, T and B lymphocytes, mast cells, and antigen presenting cells(APC) such as macrophages, Dendritic cells and other distinct cell types including fibroblasts, Carcinoma associated fibroblast, smooth musclecells, myo-fibroblast, endothelial cells and their precursors, pericytes. Recent data have demonstrated a role of these individual components, in particular carcinoma associated fibroblasts, macrophages and endothelial cells, in promoting tumor growth and progression (1-2). The tumorstroma has an indispensable role in acquiring hallmark capabilities. The stroma provides support with growth factors (GM-CSF,G-CSF,M-CSF; VEGF; TGF), cytokines (IL-1,IL-4,IL-5,IL-6,IL-10,IL-13, TNF-Alfa, Interferon -Gamma), chemokines (CCL2,CCL4,CCL5, CXCL1, CXCL12 and CXCL8) along with COX2 which, secrete prostaglandin E2,promotes the generation of Myeloid derived suppressor cells. # III. Role of mdsc in Immunosuppression These are immature heterogeneous myeloid cells that fail to terminally differentiate in to granulocytes, dendritic cells or macrophages on chronic inflammatory conditions and exhibit immunosuppressive function by multiple mechanism. Their broadly distinct phenotypical characteristics, Among human MDSCs, the two subsets can be distinguished as Granulocytic and Monocytic(3). which, is responsible for immuno-modulatory activity in tumor microenvironment by evading active immune system by various factors by potent inhibitors of both antigenic -specific and non-specific T-cell activation. These factors are arginase, nitric oxide, Reactive oxygen species (ROS), PGE2, Cystein, peroxynitrate. An important mutagenic factor frequently abundant in an inflammatory microenvironment is ROS (eg. Oxygen ions and peroxides) results from oxidative stress induced by phagocytic cells.ROS are highly reactive, unstable molecules that damage DNA increases the cell mutation rate, thus favouring the appearance of clones with oncogenic properties. Potential key mechanism of MDSC -induced CD8+ T-cell immunosuppression in tumor bearing hosts by increased NADPH oxidase, NOX 2 activity (4-5). Nitric oxide is produced by MDSC by utilising L-arginine as substrate for nitric oxide synthase (6,7). Which, suppresses T-cell activation, adhesion, proliferation and migration (8)(9)(10)(11)(12)(13).It also suppresses Tcell function, particularly CD8+ T cells by blocking the activation of signalling molecules in T cells, including JAK1(Janus activated kinase 1), STAT5, ERK and Akt (8,11). It has also been shown to inhibit MHC class 2 expression and promote CD8 T-cell apoptosis (14,15). Other important moderator synthesize by MDSC is Arginase. L-Arginine is a conditionally essential aminoacid and metabolized by arginases and nitric oxide synthases to produce either L-ornithine and urea (16,17,18). L-arginine is an amino acid required for Tcell function and proliferation. L-arginine deprivation has been reported to induce T-cell dysfunction and suppression of T-cell function (19,20,21).These mechanisms seem to contribute to the protumoral function of MDSC (22). MDSC are copious producers of peroxynitrate and increased levels are associated with tumor progression by inhibiting antigen specific, cytotoxic T-cell responses (23). Cysteineis an essential amino acid required for T-cell activation, differentiation and proliferation (24). MDSC mediated cysteine depletion, block activation of T-cell from the local microenvironment results in the inhibition of T-cell activation and function (25). PGE2 is an eicosanoids synthesise by COX2produced and secreted by MDSC, mediated over expression of arginase, Corelated with their pro-inflammatory and immunosuppressive properties, further inhibiting the activity of CD8+ T cells. MDSCs immunosuppressive function, activation and proliferation is activated by IFN-gamma, TLR ligands, IL-13, IL-4, and TGF -beta, which trigger STAT3and NF-kb signalling pathways (26,27,28). These various factors are produced during the course of inflammation following cellular stresses, in response to hormones, growth factors, endotoxin and inflammatory cytokines or by growing tumors which induces angiogenesis, apoptosis, chronic inflammation and immunosuppression (28,29). # IV. Interaction of mdsc with other Immunecells MDSCs communication network between macrophages and DCs that promotes and maintains an immunosuppressive microenvironment. This communication is mainly mediated by inflammatory mediators IL-1beta, IL-6, IL-10, PGE-2, and TGF -beta (30,31). The activating NK receptors inhibited by IDO (Indoleamine 23-dioxygenase) andPGE2 are counteracted by NKG2A an inhibitory receptor utilized by both T and NK cells (32). An early response of damaged tissue is production of IL-8 by the epithelial cell itself, which together with macrophages and mast cells secrete TNF-alfa and histamine allows neutrophil extravasion to injure site initiating inflammation. Chemokines secreted by endothelial cells and macrophages brings inflammatory and immune cells to the site of inflammation (33). Among inflammatory factors promoting proliferation are TGFbeta, fibroblast growth factor, epithelial growth factor, TGF-beta synthesized by mast cells, macrophages and lymphocytes as an inactive precursor in inflammatory microenvironment activated by proteases. TGF-beta promotes mesenchymal Cell proliferation and immunomodulation by promoting N2 neutrophils and M2 macrophages, facilitates tumor invasion and metastasis (34,35). LPS is a known activator of macrophage cross talk with MDSC in the presence of LPS. Later LPS binds to LPS binding protein. Which helps in transfer ofLPS to the membrane bound receptor CD14 through TLR4signalling pathway. TLR4 signalling pathway gets activated by CD14 binds with TLR4 further downstream activation of NF-kb driving MDSC production of IL-10 resulting in immunosuppression and immune evasion by promoting M2 polarization of macrophages (36). Alternatively activated macrophages(M2 type) are an important source of both Fibroblast growth factors, and Endothelial growth factors activated by cytokines such as IL-4, IL-5, IL-6, IL-9, IL-13, IL-17 and TGF-beta acts as a immunosuppressor towards Treg (Regulatory T cell) cells maintain immunosuppressive microenvironment (37,38). Tumor stromacan also suppress immune effector function. Extra cellular accumulation of lactate, adenosine, VEGF under hypoxic condition activated by hypoxia inducible transcriptional factor (HIF) further induces angiogenesis. Cross talk between MDSC and dendritic cells in presence of cytokines such as IL-4, GM-CSF and PGE2 results in decrease in production of mature dendritic cells , blocking T-cell production of IFN-gammaand dendritic cells production of Proinflammatory cytokine IL-23driving the proliferation and inflammatory function of Th17 cells. Which suppresses both adaptive and innate immunity, due to immunosuppressive network, the immature dendritic cell fail to activate to become mature dendritic cell on antigenic presentation. So, the activation ofCD4+ and CD8+ T cells don't take place. All together co-operate to inhibit Dendritic cell antigen-processing, presenting activity and dendritic cell tolerance (39)(40)(41)(42)(43)(44)(45)(46)(47).All these factors contribute to pro-tumoral activity, tumor progression, invasion and metastasis. Inflammation is considered to be a' Seventh hallmark' of cancer (4). Myeloid derived suppressor cells are immature myeloid cells of myeloid progenitor cells upon chronic inflammation. They are of two types Monocystic-MDSC and Granulocytic-MDSC. Myeloid derived suppressor cells induce immunosuppression by various mechanisms suppresses both innate and adaptive immunity, it also possess plasticity and the type of MDSC in tumor microenvironment determines the immunesuppression. Complex interactions between MDSC and immune cells and their role in immunesuppression need to be studied. Understanding of MDSC biology, chronic inflammatory mediators, which helps in MDSC recruitment, generation, activation and their role in immunosuppression must be revealed for therapeutic strategy and its role in tumor prognosis. # V. Conclusion Thorough understanding of immune cells of Oral tumor microenvironment , role of immune cells such as Macrophages, T lymphocytes and natural killer cells which, drive towards tumorigenesis. Role of Inflammatory cells and their mediators such as cytokines, their interactions with myeloid derived suppressor cells are major immunosuppressor and immune evasion cells. Phonotypical and functional role of myeloid derived suppressor cells in oral tumor microenvironment linking between inflammation and oral cancer. Hence, modulating targeted or combined immune cells in oral tumor microenvironment, could possibly hold a future therapeutic opportunity with better survival rate and less possible complications. # Abbreviations ![HGF, Hepatic growth factor, VEGF, Vascular endothelial growth factor, MMP-9, Matrix mettaloproteinases-9, COX2, Cyclo-oxygenase2, INOS, Inducible nitric oxide synthase, ROS, Reactive oxygen species, PDGF, Platelet derived growth factor, EGF, Epidermal growth factor, FGF, Fibroblast growth factor, TNF-Alfa, Tumour necrosis factor-Alfa, IFN-Beta, Interferon Beta, IL-10, Interleukin 10, TGF-Beta, Transforming growth factor-Beta, CCL17, CC Chemokine ligand 17, CCL18, CC Chemokine ligand 18, CCL22, CC chemokine ligand 22, PGE2, Prostaglandin E2, IDO, Indoleamine 2,3 -dioxygenase, UPA, Urokinase plasminogen activator, IL-2, Interleukin 2, IL-4, Interleukin 4, IL-6, Interleukin -6, IFN-Gamma, Interferon Gamma, COX-1, Cyclo-oxygenase 1, COX2, Cyclo-oxygenase 2, NF-KB, Nuclear factor KB, MCP-1, Macrophage/Monocyte chemoattractant protein-1, M-CSF, Macrophage colony stimulating factor, IL-17, Interleukin 17, CD4+ Th17, CD4+ T helper lymphocyte17, MDSC, Myeloid derived suppressor cells, SR-A, The class A macrophage scavenger receptor msr1, Volume XVI Issue II Version I © 2016 Global Journals Inc. (US) , Granulocyte Macrophage-Colony stimulating factor, G-CSF, Granulocyte colony stimulating factor, STAT3, Signal transducer and activator of transcription 3, bFGF-basic fibroblast growth factor, MMPS, Matrix metallo proteinases, HIF-1 Alfa, Hypoxia-Inducible factor Alfa. T reg cell, T regulatory cell, T h1, T helper1, Th2, T helper 2, TAM, Tumor associated macrophages, TLR, Toll like receptor, DC, Dendritic cells, NK cells, Natural killer cells, HLA, Human leucocyte antigen, MHC 1, Major histocompatibility antigen 1, Akt, Protein kinase B, ERK, Extracellular signal-regulated kinase.Volume XVI Issue II Version I](image-2.png "") © 2 016 Global Journals Inc. (US) * Hallmarks of cancer; Interactions with the tumorstroma APietras K, Ostman Exp cell Res 316 2010 * Regulation of tumor metastasis by myeloid-derived suppressor cells.Annual review of medicine TCondamine IRamachandran JIYoun DIGabrilovich 2015 66 * Myeloid-derived suppressor cell heterogeneity and subset definition EPeranzoni SZilio IMarigo LDolcetti PZanovello SMandruzzato VBronte Curr OpinImmunol 22 2010 * Cancer -related inflammation, the seventh hallmark of cancer; links to genetic instability FColotta PAllavena ASica CGarlanda MantovaniA Carcinogenesis 30 2009 * Oxidative stress, tumor microenvironment, and metabolic reprogramming: a diabolic liaison TFiaschi PChiarugi International Journal of Cell Biology 20 2012 * Nitric oxide inhibits the secretion of T-helper 1-and T-helper 2-associated cytokines in activated human T cells HBauer TJung DTsikas DOStichtenoth JCFrolich CNeumann Immunology 90 1997 * Effect of exogenous nitric oxide on murine splenic immune response induced by Aggregatibacter actinomycetemcomitans lipopolysaccharide WSosroseno PSBird G JSeymour Anaerobe 15 2009 * Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/ STAT5 signaling pathway RMBingisser PATilbrook PGHolt Kees U R J Immunol 160 1998 * Disparate functions of myeloid-derived suppressor cells in cancer metastasis LauraEEdgington-Mitchell BelindaSParker Cancer Forum 38 2014 * Nitric oxide involvement in tumorinduced immunosuppression PLejeune PLagadec NOnier DPinard HOhshima JFJeannin J Immunol 152 1994 * Myeloid suppressor lines inhibit T cell responses by an NOdependent mechanism AMazzoni VBronte AVisintin J HSpitzer EApolloni PSerafini PZanovello DMSegal J Immunol 168 2002 * Augmentation of an antitumor CTL response In vivo by inhibition of suppressor macrophage nitric oxide MMedot-Pirenne M JHeilman MSaxena P EMcdermott CDMills J Immunol 163 1999 * Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells KSato KOzaki IOh AMeguro KHatanaka TNagai KMuroi KOzawa Blood 109 2007 * Inhibition of MHC II gene transcription by nitric oxide and antioxidants OHarari JKLiao Curr Pharm Des 10 2004 * Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction LRivoltini MCarrabba VHuber CCastelli LNovellino PDalerba Immunol Rev 188 2002 * Nitric oxide and the immune response CBogdan Nat Immunol 2 2001 * Regulation of enzymes of the urea cycle and arginine metabolism SMMorris Jr Annu Rev Nutr 22 2002 * Subsets of myeloid-derived suppressor cells in hepatocellular carcinoma express chemokines and chemokine receptors differentially WZhao YXu JXu DWu BZhao ZYin XWang International immunopharmacology 26 2 2015 * IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice VBronte PSerafini DeSanto CMarigo ITosello VMazzoni A J Immunol 170 2003 * Myeloid-derived cells are key targets of tumor immunotherapy JMedina-Echeverz FAranda PBerraondo Oncoimmunology 3 4 2014 * Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives PCRodriguez ACOchoa Immunol Rev 222 2008 * Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment KHParker DWBeury SOstrand-Rosenberg Myeloid Advances in Cancer Research 12 2015 * Altered recognition of antigen is a mechanism of SNagaraj KGupta VPisarev LKinarsky SSherman LKang DLHerber JSchneck DIGabrilovich * CD8+ T cell tolerance in cancer Nat Med 13 2007 * Phenotypes, accumulation, and functions of myeloid-derived suppressor cells and associated treatment strategies in cancer patients JJiang WGuo XLiang Human immunology 75 11 2014 * Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine MKSrivastava PSinha VKClements PRodriguez SOstrand-Rosenberg Cancer Res 70 2010 * Myeloid regulatory cells in tumor spreading and metastasis AAKeskinov MRShurin Immunobiology 220 2 2015 * Myeloidderived suppressor cells: linking inflammation and cancer SOstrand -Rosenberg PSinha Journal of immunology 188 8 2009 * Pivotal advance; Tumor -mediated induction of myeloid -derived suppressor cells and M2-polarized macrophages by altering intracellular PGE2 catabolism in myeloid cells EEruslanov IDaurkin JOrtiz JVieweg SKusmartsev J. Leukol. Biol 88 2010 * Prostaglandin E2 at new glance; Novel insights in functional diversity offer therapeutic chances DFLegler MBruckner EVetz-Von Allmen PKrause International. Journal of Biochem cell Biol 42 2010 * Cross-talk between myeloid -derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor -induced immune suppression SOstrand -Rosenberg PSinha BeuryDw VKClements Seminars in cancer biology 22 4 2012 * Myeloid -derived suppressor cells: mechanisms of action and recent advances in their role in transplant tolerance NDilek RVuillefroy D Silly GBlancho BVanhove Frontiers in immunology 3 2012 * Human Leukocyte antigen E contributes to protect tumor cells from lysis by natural killer cells ELo Manaco ETremante CCerboni EMelluci LSibilio AZingoni Neoplasia 13 2011 * Essential involvement of interleukin -8 (IL-8) in acute inflammation AHarda NSekido TAkahoshi TWada NMukaida KMatsushima Journal of leukocyte biology 56 1994 * Mesenchymal stem cells play a potential role in regulating the establishment and maintenance of epithelial -mesenchymal transition in MCF7 human breast cancer cells by paracrine and induced autocrine TGF-beta QXu LWang HLi International journal of oncology 41 2012 * Transforming growth factor beta -induced epithelial -mesenchymal transition increases cancer stem -like cells in the PANC-1 cell line HWang JWu YZhang Oncology 3 letters2012 * Lipopolysaccharide induces physical proximity between CD14 and toll-like receptor 4 (TLR4) prior to nuclear translocation of NF-kappa B QJiang SAkashi KMiyake HRPetty J Immunol 165 2000 * Interleukin -6(IL-6) signaling regulates anchorage independent growth, proliferation, adhesion and invasion in human ovarian cancer cells YWang LLi XGuo Cytokine 59 2012 * Interleukin -6 promoter variants, prostate cancer risk and survival EATindall GSeveri NHoang The prostate 72 2012 * Divergent effects of hypoxia on dendritic cell functions AMancino TSchioppa PLarghi Blood 112 2008 * Human dendritic cells differentiated in hypoxia down modulate antigen uptake and change their chemokine expression profile ARElia PCappello MPuppo Journal of leukocyte biology 84 2010 * HIF-dependent induction of adenosine receptor A2b skews human dendritic cells to a Th2 -stimulating phenotype under hypoxia MYang CMa SLiu Immunology and cell biology 88 2010 * Myeloid derived suppressor cells in the tumor microenvironment MDouglas DmitryIGabrilovich * Expect the unexpected The journal of Clinical investigation 7 2015 * Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines IPoschke YMao LAdamson FSalazar-Onfray GMasucci RKiessling Cancer Immunol 8 Immunother2011 * Understanding the IL-23-IL-17 immune pathway BSMckenzie RAKastelein DJCua Trends Immunol 27 2006 * Myeloid-Derived Suppressor Cells and Tumor Growth. In Interaction of Immune and Cancer Cells LRaffaghello GBianchi Journal of cancer 2014 * Myeloidderived suppressor cells in cancer: therapeutic, predictive, and prognostic implications CMDiaz-Montero JFinke AJMontero Seminars in oncology 41 2014 * IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis MWTeng DMAndrews NMclaughlin VonScheidt BNgiow SFMoller A Proc Natl Acad Sci 107 2010 * Effect of exogenous nitric oxide on murine splenic immune response induced by Aggregatibacteractinomycetemcomitans lipopolysaccharide WSosroseno Anaerobe 15 2009 * Macrophagederivednitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5signaling pathway RMBingisser J Immunol 160 1998 * Nitric oxide mediation of active immunosuppression associated with graft-versus hostreaction PBobe Blood 94 1999 * Nitricoxide involvement in tumor-induced immunosuppression PLejeune J Immunol 152 1994 * Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism AMazzoni J Immunol 168 2002 * Augmentation of an antitumor CTL response in vivo by inhibition of suppressor macrophage nitric oxide MMedot-Pirenne J Immunol 163 1999 * Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells KSato Blood 109 2007 * Inhibition of MHC II gene transcription by nitric oxide and antioxidants OHarari Curr Pharm Des 10 2012 * Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction LRivoltini Immunol Rev 188 2013 * Nitric oxide and the immune response CBogdan Nat Immunol 2 2011 * Regulation of enzymes of the urea cycle and arginine metabolism SMMorris Annu Rev Nutr 22 2002 * Arginine metabolism: nitric oxide and beyond GWu Biochem J 336 1998 * IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice VBronte J Immunol 170 2003 * Regulation of immune responses by L-arginine metabolism VBronte Nat Rev Immunol 5 2005 * Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives PCRodriguez Immunol Rev 222 2008 * Arginase -1 production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigenspecific T-cell responses PCRodriguez Cancer Res 64 2004 * Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer SNagaraj Nat Med 13 2007 * A potent suppressor of lymphoma growth by inhibition of the x(c)-cystine transporter: anew action for an old drug PWGout oncogene 15 2011 * Myeloid-derived suppressor cells inhibit T-cell activation by depletingcystine and cysteine MKSrivastava Cancer Res 70 2010 * Myeloid regulatory cells in tumor spreading and metastasis AAKeskinov MRShurin Immunobiology 220 2 2015 Feb 28 * Myeloidderived suppressor cells: linking inflammation and cancer SOstrand -Rosenberg Journal of immunology 188 2009 * Pivotal advance ; Tumormediated induction of myeloid -derived suppressor cells and M2-polarized macrophages by altering intracellular PGE2 catabolism in myeloid cells EEruslanov J. Leukol. Biol 88 2010 * Prostaglandin E2 at new glance; Novel insights in functional diversity offer therapeutic chances DFLegler International. Journal of Biochem cell Biol 42 2010 * Cross-talk between myeloid -derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor -induced immune suppression SOstrand -Rosenberg Seminars in cancer biology 22 2012 * Myeloid -derived suppressor cells: mechanisms of action and recent advances in their role in transplant tolerance NDilek Frontiers in immunology 3 2014 * Human Leukocyte antigen E contributes to protect tumor cells from lysis by natural killer cells ELo Manaco Neoplasia 13 2011 * Essential involvement of interleukin -8 (IL-8) in acute inflammation AHarda Journal of leukocyte biology 56 1994 * Mesenchymal stem cells play a potential role in regulating the establishment and maintenance of epithelial -mesenchymal transition in MCF7 human breast cancer cells by paracrine and induced autocrine TGF-beta QXu International journal of oncology 41 2012 * Transforming growth factor beta -induced epithelial -mesenchymal transition increases cancer stem -like cells in the PANC-1 cell line HWang Oncology letters 3 2012 * Lipopolysaccharide induces physical proximity between CD14 and toll-like receptor 4 (TLR4) prior to nuclear translocation of NF-kappa B QJiang J Immunol 165 2000 * Interleukin -6(IL-6) signaling regulates anchorage independent growth, proliferation, adhesion and invasion in human ovarian cancer cells YWang Cytokine 59 2012 * Interleukin -6 promoter variants, prostate cancer risk and survival. The prostate EATindall 2012 72 * Divergent effects of hypoxia on dendritic cell functions AMancino Blood 112 2008 * Human dendritic cells differentiated in hypoxia down modulate antigen uptake and change their chemokine expression profile ARElia Journal of leukocyte biology 84 2010 * HIF-dependent induction of adenosine receptor A2b skews human dendritic cells to a Th2 -stimulating phenotype under hypoxia MYang Immunology and cell biology 88 2010 * Mechanisms and functional significance of tumour-induced dendriticcell defects DGabrilovich Nat Rev Immunol 4 2014 * Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines IPoschke Cancer Immunol Immunother 8 2011 * Understanding the IL-23-IL-17 immune pathway BSMckenzie Trends Immunol 27 2006 * IL-23 drives a pathogenic T cell population that induces autoimmune inflammation CLLangrish J Exp Med 201 2005 * IL-23 promotes tumour incidence and growth JLLangowski Nature 442 2006 * IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis MWTeng Proc Natl Acad Sci 107 2010 * New insights into cancer immunoediting and its three component phaseselimination, equilibrium and escape DMittal Curr opin immunol 27 2014